Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 5 Jun 2006 |
| 120,350 Orion A-shares converted into B-shares | 2 Jun 2006 |
| Erkki Etola resigns from the Board of Directors of Orion Corporation | 22 May 2006 |
| Orion update on Simdax: Additional Phase 3 study under consideration | 18 May 2006 |
| Orion Group Interim Report 1-3/2006 | 8 May 2006 |